
    
      Objective:To observe the secondary clinical effect of the Deng Zhan Sheng Mai capsule on
      ischemic stroke patients.

      Methods:3143 subjects suffering from acute ischemic stroke are included in 83 clinical
      research centers all over China. The subjects are randomly divided into two groups:The
      treating group and the placebo group.Both groups accept the basic therapy and test drug.The
      basic therapy included antiplatelet aggregation,stroke health education,management of blood
      pressure,blood lipid and blood glucose,etc.The patients in Dengzhan Shengmaigroup take Deng
      Zhan Sheng Mai capsule and the placebo group take the placebo drug for twelve months.Then all
      of the subjects are visited on the 30th,90th,180th,360th day after inclusion. Primary
      endpoints(cerebral infarction,intracerebral hemorrhage,subarachnoid hemorrhage) and secondary
      endpoints(cardiovascular events,peripheral arterial disease),functional disability are
      observed at each follow up.
    
  